PharmaMar Announces New Advances in Their Compounds Yondelis®, plitidepsin and lurbinectedin at ASCO 2016

MADRID, May 19, 2016 /PRNewswire/ --

• During this event, where more than 30.000 oncologists from around the world will meet, various studies relating to the three compounds of marine origin, researched and developed by PharmaMar, will be presented    

• In an oral session, a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with multiple myeloma will be presented  

PharmaMar (MSE:PHM) will present the data obtained from various clinical studies carried out with three of their antitumoral compounds of marine origin: Yondelis®, plitidepsin and lurbinectedin, during the 52^nd Congress of the American Society of Clinical Oncology (ASCO), that will be held from June 3^rd to 7^th in Chicago (USA). At this prestigious international encounter, more than 30.000 oncologists from around the world will meet to discuss, analyze, and exchange knowledge on the progress in the treatment of different types of cancers.

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

Studies relative to these three molecules, discovered and developed by PharmaMar, will be presented during this congress. These studies have been selected either for oral or poster presentations or poster debates. At ASCO 2016, PharmaMar will present the results of a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with multiple myeloma.

"The principle objective of PharmaMar is to investigate new compounds of a marine origin with a novel mechanism of action that provides a progress in the treatment of certain types of oncological tumors, and an important contribution in healthcare for the patient", explains Dr Nadia Badri, VP Medical Affairs at PharmaMar's oncology business unit.

Dr Arturo Soto, Director of Clinical Development at PharmaMar's Oncology Unit, points out that "the results that we are going to present at ASCO 2016 are an example of how we are progressing in this field, and that we can build on an innovative and promising pipeline of compounds for different types of cancers".

Meeting abstracts are available at http://abstracts.asco.org

Studies highlighted at ASCO 2016 

Yondelis^® (trabectedin)  

Trabectedin is a novel, multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, Ecteinascidia turbinata. The drug exerts its activity by targeting the transcriptional machinery and impairing DNA repair. 

• Patient-Reported Outcomes from Randomized, Phase-3 study of Trabectedin (T) vs. Dacarbazine (D) in Advanced Leiomyosarcoma (LMS) or Liposarcoma (LPS) (Abstract #11061) - sponsored by Janssen Products, L.P    

Poster session: Sarcoma. Monday, June 6^th from 8:00 a.m. to 11:30 a.m

Lead author: George Demetri, MD et al. Dana-Farber Cancer Institute, Boston, MA, USA.

• Trabectedin (T)-related liver toxicity: Results of a pharmacokinetic study with T in patients with hepatic dysfunction (OVC1004) and experience from a phase 3 clinical trial (SAR3007) (Abstract #11064) - sponsored by Janssen Products, L.P 

Poster session: Sarcoma. Monday, June 6^th from 8:00 a.m. to 11:30 a.m

Lead author: Emiliano Calvo, MD et al. Centro Integral Oncológico Clara Campal (CIOCC), Madrid Norte Sanchinarro Hospital, Spain

• Cardiac Safety Analysis of Trabectedin (T) vs. Dacarbazine (D) in Patients (Pts) with Advanced Leiomyosarcoma (LMS) or Liposarcoma (LPS) After Prior Anthracycline Chemoterapy (Abstract #11060) - sponsored by Janssen Products, L.P  

Poster session: Sarcoma. Monday, June 6^th from 8:00 a.m. to 11:30 a.m

Lead author: Scott M. Schuetze, MD et al. Michigan University, Ann Arbor, USA.

• A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): an Italian Sarcoma Group (ISG) study (TOMAS study) (Abstract #11018)

Poster session: Sarcoma. Monday, June 6^th from 8:00 am to 11:30 am

Discussed at the Poster Discussion Session on Monday, June 6^th from 3:00 pm to 4:15 pm at S406

Lead author: Giovani Grignani, MD, et al. Istituto per la Ricerca e la Cura del Cancro di Candiolo, Italy

Plitidepsin  

Plitidepsin is an antitumor drug of marine origin, at the investigational phase for hematological tumors, including a phase Ib study in relapsed and refractory multiple myeloma, in triple combination with bortezomib and dexamethasone, along with a phase II study in relapsed and refractory angioimmunoblastic T-cell Lymphoma. Recently, plitidepsina showed positive results in a pivotal study in combination with dexamethasone in patients with multiple myeloma.

• Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. (Abstract #8006) 

Oral abstract session: Hematologic Malignancies - Plasma Cell Dyscrasia. Friday, June 3^rd from 3:00 pm to 6:00 pm. Presentation time/Duration: 5:00 pm a 5:12 pm. Speaker: María Victoria Mateos, MD University Hospital of Salamanca, Spain

Lead author: María Victoria Mateos, MD et al.

PM1183 (lurbinectedin) 

PM1183 is compound under clinical investigation, inhibitor of the RNA polymerase II enzyme. It is essential for the transcription process, which inhibits tumor growth, and resulting in tumor death. The antitumor efficacy of PM1183 is being investigated in various types of solid tumors.

• CORAIL trial: Randomized Phase III Study of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin (PLD) or Topotecan (T) in Patients with Platinum-resistant Ovarian Cancer. (Abstract #TPS5597) 

Poster session: Gynecologic Cancer. Monday, June 6^th from 1:00 pm to 4:30 pm.

Lead author: S. Gaillard et al. MD, Duke Cancer Institute, Durham, USA.

Media Relations: +34-638-79-62-15

Investor Relations: +34-914444500